Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXG001-307 in infants with type 1 spinal muscular atrophy
CTR20222539Phase 2Active
- Sponsor
- Hangzhou RebornGene Therapeutics Co., Ltd.
- Start
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes, AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of EXG001-307 in spinal muscular atrophy type 1, sponsored by Hangzhou RebornGene Therapeutics Co., Ltd.. Started Feb 2023; status: active.
02
Drugs
EXG001-307
03
Conditions
spinal muscular atrophy type 1
Beyond the preview
Go deeper on CTR20222539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222539.